Literature DB >> 24948623

Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database.

Jorge J Castillo1, Adam J Olszewski2, Angel M Cronin3, Zachary R Hunter1, Steven P Treon1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24948623     DOI： 10.1182/blood-2014-05-574871

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  20 in total

1.  Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century.

Authors:  Janick Weberpals; Dianne Pulte; Lina Jansen; Sabine Luttmann; Bernd Holleczek; Alice Nennecke; Meike Ressing; Alexander Katalinic; Maximilian Merz; Hermann Brenner
Journal:  Haematologica       Date:  2017-03-09       Impact factor: 9.941

Review 2.  Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.

Authors:  Jorge J Castillo; M Lia Palomba; Ranjana Advani; Steven P Treon
Journal:  Ther Adv Hematol       Date:  2016-06-13

3.  Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.

Authors:  Adam J Olszewski; Steven P Treon; Jorge J Castillo
Journal:  Oncologist       Date:  2016-07-29

Review 4.  Toward personalized treatment in Waldenström macroglobulinemia.

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.

Authors:  Jorge J Castillo; Shirley D'Sa; Michael P Lunn; Monique C Minnema; Alessandra Tedeschi; Frederick Lansigan; M Lia Palomba; Marzia Varettoni; Ramon Garcia-Sanz; Lakshmi Nayak; Eudocia Q Lee; Mikael L Rinne; Andrew D Norden; Irene M Ghobrial; Steven P Treon
Journal:  Br J Haematol       Date:  2015-12-21       Impact factor: 6.998

6.  Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.

Authors:  Jorge J Castillo; Ramon Garcia-Sanz; Evdoxia Hatjiharissi; Robert A Kyle; Xavier Leleu; Mary McMaster; Giampaolo Merlini; Monique C Minnema; Enrica Morra; Roger G Owen; Stephanie Poulain; Marvin J Stone; Constantine Tam; Marzia Varettoni; Meletios A Dimopoulos; Steven P Treon; Efstathios Kastritis
Journal:  Br J Haematol       Date:  2016-07-05       Impact factor: 6.998

Review 7.  Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.

Authors:  Prashant Kapoor; Stephen M Ansell; Rafael Fonseca; Asher Chanan-Khan; Robert A Kyle; Shaji K Kumar; Joseph R Mikhael; Thomas E Witzig; Michelle Mauermann; Angela Dispenzieri; Sikander Ailawadhi; A Keith Stewart; Martha Q Lacy; Carrie A Thompson; Francis K Buadi; David Dingli; William G Morice; Ronald S Go; Dragan Jevremovic; Taimur Sher; Rebecca L King; Esteban Braggio; Ann Novak; Vivek Roy; Rhett P Ketterling; Patricia T Greipp; Martha Grogan; Ivana N Micallef; P Leif Bergsagel; Joseph P Colgan; Nelson Leung; Wilson I Gonsalves; Yi Lin; David J Inwards; Suzanne R Hayman; Grzegorz S Nowakowski; Patrick B Johnston; Steven J Russell; Svetomir N Markovic; Steven R Zeldenrust; Yi L Hwa; John A Lust; Luis F Porrata; Thomas M Habermann; S Vincent Rajkumar; Morie A Gertz; Craig B Reeder
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 31.777

8.  In silico biophysics and hemorheology of blood hyperviscosity syndrome.

Authors:  Elahe Javadi; Yixiang Deng; George Em Karniadakis; Safa Jamali
Journal:  Biophys J       Date:  2021-06-02       Impact factor: 3.699

9.  Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.

Authors:  Jorge J Castillo; Jithma P Abeykoon; Joshua N Gustine; Saurabh Zanwar; Kirsten Mein; Catherine A Flynn; Maria G Demos; Maria L Guerrera; Amanda Kofides; Xia Liu; Manit Munshi; Nickolas Tsakmaklis; Rebecca King; Guang Yang; Zachary R Hunter; Ranjana H Advani; Maria Lia Palomba; Stephen M Ansell; Morie A Gertz; Prashant Kapoor; Steven P Treon
Journal:  Br J Haematol       Date:  2020-11-18       Impact factor: 6.998

10.  Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016.

Authors:  Nicole H Dalal; Graça M Dores; Rochelle E Curtis; Martha S Linet; Lindsay M Morton
Journal:  Br J Haematol       Date:  2020-02-23       Impact factor: 8.615
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.